期刊文献+

父方否决细胞对小鼠半相合干细胞移植模型移植物抗宿主病的预防作用

Role of paternal veto cells in preventing graft-versus-host disease after HLA-haploidentical stem cell transplantation in mice
下载PDF
导出
摘要 目的探讨父方否决细胞对小鼠半相合干细胞移植模型移植物抗宿主病(GVHD)是否起预防作用。方法以B6CF1(H-2b/d)作为半相合干细胞移植的受鼠,给予9.0Gy全身照射后4h,单纯照射组经尾静脉注射0.3mlD-Hank's液,不进行细胞移植;对照组经尾静脉注射C57BL/6小鼠混合细胞悬液(4.5×106骨髓细胞+3.0×107脾细胞),但不进行其他治疗处理;实验组于移植4d后经尾静脉注射BALB/c小鼠脾细胞悬液(数量分别为5.0×106、1.0×107),然后观察其造血恢复、植入及移植物抗宿主病(GVHD)的情况。结果由于没有给予GVHD防治措施,对照组受鼠GVHD的发生率和死亡率分别为10/10和10/10;而1/6量否决细胞组小鼠GVHD的发生率为5/10,30d生存率增加至5/10(P<0.01),5只因GVHD死亡的受鼠中位生存期为20d,较对照组(中位生存期14d)有显著性差异(P<0.05);1/3量否决细胞组小鼠GVHD的发生率为2/10,30d生存率增加至8/10,中位生存期延长至30d以上(P<0.05)。结论半相合干细胞移植后输注父方否决细胞,可以诱导特异性免疫耐受,显著降低半相合干细胞移植GVHD的发生率。 Objective To explore the role of paternal veto cells in preventing graft-versus-host disease (GVHD) after related HLA- haploidentical stem cell transplantation in mice. Methods MHC-haploidentical recipient B6CFl (H-2 b/d) mice pretreated with total body irradiation at 9.0 Gy for 4 h before transplantation. The recipient mice were divided into 4 groups, and in the irradiation group, only injection of 0.3 ml D-Hank's liquid was given through the tail vein; in the control group, the mice received injection through the tail vein of 4.5×10^6 bone marrow cells mixed with 3.0×10^7 spleen cells from C57BU6 mice without the preventive measures of GVHD; the mice in the two experiment groups received cell transplantation in the same manner, and on day 4 after transplantation, 5.0×10^6 and 1.0×10^7spleen cells from BALB/c mice were injected through tail vein, respectively. The hematopoietic recovery, engraftment and GVHD of the recipient mice were observed. Results Without any treatment, all mice in the control group developed GVHD and died after transplantation. In the 10 mice with injection of 5.0× 10^6 spleen cells, GVHD occurred in 5 mice with a 30-day survival rate of 50%; the median survival time of the mice with GVHD was 20 days, significantly longer than that of the control mice (14 days, P〈0.05). In the 10 mice injected with 1.0×10^7 spleen cells, 2 developed GVHD and the 30-day survival rate was 80% (8/10) with a median survival time of 30 days, significantly longer than that of mice with injection of 5.0×10^6 spleen cells and the control mice (P〈0.05). Conclusion Paternal veto cell transplantation can decrease the occurrence of GVHD after related HLA haploidentical stem cell transplantation in mice.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2008年第1期79-81,共3页 Journal of Southern Medical University
基金 成都军区医学科研计划课题(MB07027)~~
关键词 否决细胞 半相合干细胞移植 移植物抗宿主病 veto cells HLA- haploidentical stem cell transplantation graft-versus-host disease
  • 引文网络
  • 相关文献

参考文献7

  • 1Slavin S.New strategies for bone marrow transplantation[J].Curr Opin Immunol,2000,12(5):542-51.
  • 2Aviner S,Hao X,Krauthgamer R,et al.Large-scale preparation of human anti-third-party veto cytotoxic T lymphocytes depleted of graft-versus-host reactivity:a new source for graft facilitating cells in bone marrow transplantation[J].Hum Immunol,2005,66 (6):644-52.
  • 3Chrobak P,Gress RE.Veto activity of activated bone marrow does not require perforin and Fas ligand[J].Cell Immunol,2001,208(2):80-7.
  • 4Reisner Y,Gur H,Reich-Zeliger S,et al.Hematopoietic stem cell transplantation across major genetic barriers:tolerance induction by megadose CD34 cells and other veto cells[J].Ann N Y Acad Sci,2005,1044:70-83.
  • 5Reisner Y,Gur H,Reich-Zeliger S,et al.Crossing the HLA barriers[J].Blood Cells Mol Dis,2004,33(3):206-10.
  • 6Azuma E,Yamamoto H,Kaplan J,et al.Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease[J].J Immunol,1989,143(5):1524-9.
  • 7Weiss L,Slavin S.Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin[J].Bone Marrow Transplant,1999,23(11):1139-43.
;
使用帮助 返回顶部